CBD Knee Osteoarthritis Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Karen C Johnson, MD, MPH · PRINCIPAL_INVESTIGATOR · University of Tennessee
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Knee PainDay 1 - Baseline One Visit, Day 30 - Follow-up One Visit, Day 44 - Baseline Two Visit, and Day 74 - Follow-up Two Visit
The investigators will use ecological momentary assessment to collect knee pain scores and develop pain trajectories. A Visual Analog Scale of Self-Reported Pain will be assessed at study visits and up to once a day via text message using the Wong-Baker visual analogue scale. A score of 0 is no pain and a score of 10 is severe pain. Please note this is crossover clinical trial and there are 2 Baseline Visits (One and Two). Knee Pain will be assessed at the Screening Visit as an eligibility criteria and at Baseline One Visit (Day 1), Follow-up One Visit (Day 30), Baseline Two Visit (Day 44), and Follow-up Two Visit (Day 74). The Baseline One Visit will occur 2 weeks after the Screening Visit. Change in knee pain scores on the Visual Analog Scale of Self-Reported Pain will be assessed from the Baseline One Visit to the the Follow-up One Visit and from the Baseline Two Visit to the the Follow-up Two Visit.